bpc 157 schizophrenia Frontiers The Stable Gastric Pentadecapeptide BPC

BPC-157, an experimental compound, is believed to exert its effects through multiple mechanisms, including promoting blood vessel formation (angiogenesis), enhancing tissue regeneration, and modulating various growth elements and signaling pathways involved in tissue repair

Clinical Trial Safety Data: Across multiple studies using oral and intravenous AOD-9604 for up to 24 weeks, the peptide demonstrated an excellent safety profile indistinguishable from placebo

In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it

You want a state-licensed U.S

It is not intended as medical advice, diagnosis, or treatment